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Objectives. We investigated whether bivalirudin is more effec-
tive than heparin in preventing ischemic complications in high
risk patients undergoing coronary angioplasty for thrombus-
containing lesions detected by angiography.
Background. Heparin is administered during coronary angio-
plasty to prevent closure of the dilated vessel. Bivalirudin (Hiru-
log) is a direct thrombin inhibitor that can be safely substituted
for heparin during angioplasty. Bivalirudin has several theoretic
advantages over heparin as an anticoagulant agent.
Methods. We performed an observational analysis of the Hiru-
log Angioplasty Study in which 4,098 patients with unstable or
postinfarction angina were randomized to receive either bivaliru-
din or heparin during coronary angioplasty. The study group for
this analysis consisted of 567 patients who had thrombus-
containing lesions on angiography. The primary end point was
death, myocardial infarction, emergency coronary artery bypass
graft surgery or abrupt vessel closure before hospital discharge.
Results. Patients with thrombus-containing lesions had a
higher incidence of myocardial infarction (5.1% vs. 3.2%, p 5
0.03) and abrupt vessel closure (13.6% vs. 8.3%, p < 0.001) than
those without thrombus. In patients with thrombus-containing
lesions, however, the incidence of the primary end point was not
different between the bivalirudin and heparin treatment groups.
Furthermore, no difference in the incidence of ischemic events at
6 months was seen between the treatment groups.
Conclusions. Bivalirudin is not more effective than heparin in
preventing ischemic complications in patients undergoing coro-
nary angioplasty for thrombus-containing lesions detected by
angiography. Other approaches, perhaps involving potent anti-
platelet agents, should be considered for patients with thrombus-
containing lesions.
(J Am Coll Cardiol 1997;30:1264–9)
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The direct thrombin inhibitors, such as hirudin and its ana-
logues, have several theoretic advantages over heparin. The
direct thrombin inhibitors are not dependent on a cofactor
such as antithrombin III to inhibit thrombin. Unlike heparin,
the direct thrombin inhibitors are active against clot-bound
thrombin (1) and have no known inhibitors such as platelet
factor 4 (2). In addition, the direct thrombin inhibitors are not
limited by the same pharmacokinetic and pharmacodynamic
heterogeneity as heparin (3).
Because of their potential advantages, the direct thrombin
inhibitors have been evaluated in the treatment of patients
undergoing coronary angioplasty and the treatment of patients
with unstable angina (4,5). The Hirulog Angioplasty Study (6)
was a double-blind, randomized trial comparing the use of the
direct thrombin inhibitor, bivalirudin (Hirulog), with heparin
in 4,098 patients undergoing coronary angioplasty for unstable
and postinfarction angina. In the entire cohort of patients,
bivalirudin was shown to be as effective as heparin in prevent-
ing ischemic complications after angioplasty; however, in the
prospectively stratified subgroup of patients with postinfarc-
tion angina, there was a significant reduction in the incidence
of nonfatal myocardial infarction and in the incidence of the
composite primary end point of in-hospital death, myocardial
infarction or need for emergency coronary artery bypass graft
surgery.
Although unstable angina is thought to result from plaque
rupture and thrombus formation (7–14), not all patients who
carry the diagnosis of unstable angina necessarily have demon-
strable intracoronary thrombus as the cause of their ischemic
syndrome (15–18). Angioscopic (19) and angiographic (8,15)
studies have shown, however, that patients with postinfarction
angina have demonstrable intracoronary thrombus more often
than other subsets of patients with unstable angina. The
frequent presence of active thrombus is one potential reason
why patients with postinfarction angina may derive short-term
benefit from a direct thrombin inhibitor. We therefore per-
formed further analysis of the Hirulog Angioplasty Study to
test the hypothesis that patients undergoing coronary angio-
plasty for thrombus-containing lesions on angiography have
lower rates of ischemic complications after angioplasty when
treated with bivalirudin compared with heparin.
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Methods
Study protocol. The study protocol has been previously
described (6). The Hirulog Angioplasty Study was a multi-
center, double-blind, randomized trial comparing bivalirudin
with heparin in patients scheduled to undergo conventional
balloon angioplasty for unstable or postinfarction angina at 121
medical centers in North America and Europe between March
24, 1993 and July 15, 1994. Patients were screened for enroll-
ment if they had chest pain. Inclusion criteria included con-
ventional balloon angioplasty for unstable angina defined as
crescendo, new onset or rest angina; angioplasty for postin-
farction angina ,2 weeks after myocardial infarction; and
written, informed consent. Exclusion criteria included throm-
bolytic therapy within 24 h; planned coronary atherectomy,
stent placement or laser treatment; or a planned, staged
angioplasty procedure. Of the 16,584 patients screened, 4,098
underwent angioplasty. The angiograms from 43 of these
patients were not available for this study, and the data from
these angiograms were not included in this analysis. The 567
patients who had thrombus-containing lesions on angiography
made up the study group for this investigation.
All patients received aspirin before the procedure. Patients
were randomly assigned to receive either bivalirudin or hepa-
rin during angioplasty in a double-blind manner. Patients in
the bivalirudin treatment group received a bolus of 1.0 mg/kg
body weight of bivalirudin immediately before angioplasty,
followed by an infusion of 2.5 mg/kg per h over 4 h, followed by
an infusion of 0.2 mg/kg per h over 16 to 20 h. Patients in the
heparin treatment group received a bolus of 175 U/kg of
heparin immediately before angioplasty, followed by an infu-
sion of heparin at 15 U/kg for 18 to 24 h. Measurements of
activated clotting time (Hemochron) were permitted at 5 min
and 45 min after the administration of the first bolus of the
study drug. If the activated clotting time at these times was
,350 s, a bolus of saline solution as placebo was given to
patients assigned to bivalirudin treatment, and a bolus of
15 U/kg of heparin was given to patients assigned to heparin
treatment.
Hirulog (BG8967) was supplied by Biogen, Inc. in a sterile
solution. The selection of drug dosing for this study was based
on previous experience with bivalirudin (4) and heparin (20) to
achieve an activated clotting time of ;350 s during the
coronary angioplasty procedure, followed by a steady decline
to ;150 s during the next 18 to 24 h.
End points. The primary end point of the study was any of
the following complications during the hospital period: death,
nonfatal myocardial infarction, need for emergency bypass
surgery or abrupt closure of the dilated vessel. All deaths were
classified and their timing determined by the consensus of at
least two members of the Morbidity and Mortality Classifica-
tion Committee, who had no knowledge of the treatment
assignment. The occurrence and timing of myocardial infarc-
tion were classified by the Myocardial Infarction and Ischemia
Classification Laboratory. Infarction was defined as an eleva-
tion in the total serum creatine kinase concentration to at least
twice the upper limit of normal (with at least 4.0% MB activity)
and the presence of at least one of the following: a new
two-step Q wave change (according to the Minnesota Code)
(21), persistent ST segment or T wave changes, a new left
bundle branch block or the presence of ischemic chest pain
lasting .30 min. Reinfarction was diagnosed on the basis of
another elevation of the total or creatine kinase, MB fraction
concentration above its previous nadir.
Abrupt closure of a successfully dilated vessel was classified
as either an established closure (22), defined as a total or
subtotal occlusion with Thrombolysis in Myocardial Infarction
trial (TIMI) flow grade 0 or 1 (23), or a threatened closure,
defined as .50% stenosis and reduced flow as measured on
the TIMI scale, that required additional therapy with intra-
coronary stenting, thrombolytic therapy or repeated cardiac
catheterization (20,24).
Data collection and statistical analysis. All patients were
followed prospectively from the time of enrollment until
hospital discharge by the research coordinator at each partic-
ipating center. Clinical data were submitted to the data
coordinating center (ClinTrials Research), which also sent
clinical monitors to each site every 2 weeks to verify all the
submitted data against source documents. Follow-up informa-
tion from office visits and telephone interviews of patients were
submitted to the data coordinating center on standardized case
report forms 3 and 6 months after enrollment by the site
research coordinators, who had no knowledge of the treatment
assignment.
All angiograms were reviewed in a core laboratory by
experienced angiographers who were unaware of the treatment
assignment and outcome and who coded lesion characteristics
with validated methods (8,20,25). The presence of thrombus
was defined by the angiographic appearance of a total occlu-
sion, hazy ulcerated lesion or filling defect in the ischemia-
related artery (8,9,26). A filling defect was defined as a lesion,
usually globular in shape, surrounded by contrast agent on at
least three sides, proximal or distal to a stenosis with or without
contrast staining (8). The reproducibility of the qualitative
assessment of thrombus-containing lesions was very good, with
a kappa value of 0.8 (27).
When comparing the treatment groups, we used the Fisher
exact test for categoric variables and the Mann-Whitney U test
for continuous variables with a non-normal distribution (28).
Statistical analyses were performed with SYSTAT 5.1 at
default settings.
Results
In the Hirulog Angioplasty Study, 567 (13.8%) of 4,098
patients had thrombus-containing lesions on angiography.
Randomization resulted in 301 of these patients receiving
bivalirudin and 266 receiving heparin. The significant differ-
ences that were seen in baseline clinical variables between the
two treatment groups were that patients in the bivalirudin
group were less likely to have had chest pain at rest 48 h before
angioplasty (64% vs. 72%, p 5 0.05) and that these patients
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were less likely to have received pretreatment with heparin
before randomization (34% vs. 46%, p 5 0.004) (Table 1).
Patients in the bivalirudin group had lower median value
and interquartile range (25th to 75th percentile) for activated
clotting times, measured 5 min after initial treatment, when
compared with those in the heparin group (348 s [range 318 to
390] vs. 382 s [range 342 to 427], p , 0.001). Differences in
systemic anticoagulation were probably magnified because
many patients in the heparin treatment group received an
additional bolus of heparin to maintain prespecified goals for
activated clotting time.
Patients with thrombus-containing lesions on angiography
were more likely to experience ischemic complications after
angioplasty than patients without thrombus-containing lesions
(Table 2). They had a significantly higher incidence of nonfatal
myocardial infarction (5.1% vs. 3.2%, odds ratio [OR] 1.6, 95%
confidence interval [CI] 1.1 to 2.5, p 5 0.03), as well as a
significantly higher incidence of the composite end point of
death, nonfatal myocardial infarction or need for emergency
bypass surgery (6.9% vs. 4.4%, OR 1.6, 95% CI 1.1 to 2.3, p 5
0.01). Patients with thrombus-containing lesions also had a
higher incidence of abrupt vessel closure (13.6% vs. 8.3%, OR
1.7, 95% CI 1.3 to 2.3, p , 0.001). The incidence of death in
the two groups was too small to make an informative compar-
ison.
Overall, bivalirudin treatment did not appear to reduce the
incidence of the primary end point in patients with thrombus-
containing lesions when compared with heparin treatment.
The incidence of nonfatal myocardial infarction (5.3% in
bivalirudin-treated patients vs. 4.9% in heparin-treated pa-
tients, p 5 0.85), the need for emergency bypass surgery (2.0%
vs. 1.9%, p 5 1.0) and the composite end point (7.0% vs. 6.8%,
p 5 1.0) were similar in the two groups (Table 3). The patients
in the bivalirudin group had a slightly higher rate of abrupt
vessel closure, but this did not reach statistical significance
(14.6% vs. 12.4%, p 5 0.46). The incidence of cumulative
ischemic complications (death from any cause, nonfatal myo-
cardial infarction or need for repeat revascularization) through
6 months after the initial angioplasty procedure was also
similar between the groups (26.9% in the bivalirudin group vs.
27.1% in the heparin group, p 5 0.95).
We further evaluated the outcomes in 95 of the 567 patients
with thrombus-containing lesions who had filling defects on
angiography, a lesion morphology known to be predictive of
ischemic complications and a prolonged hospital stay after
angioplasty (20). In this subgroup of 95 patients, treatment
with bivalirudin did not reduce the incidence of in-hospital
nonfatal myocardial infarction (4.0% in bivalirudin-treated
patients vs. 2.2% in heparin-treated patients, p 5 1.0), the
need for emergency bypass surgery (0.0% vs. 0.0%), the
composite end point (4.0% vs. 2.2%, p 5 1.0) and abrupt vessel
closure (20.1% vs. 11.1%, p 5 0.27).
Discussion
Thrombus-containing lesions. The effective treatment of
thrombus-containing lesions on angiography continues to be a
major challenge in interventional cardiology. Numerous stud-
ies have demonstrated that patients who undergo angioplasty
for thrombus-containing lesions are at higher risk of experi-
encing ischemic complications compared with patients without
intracoronary thrombus (20,29–33). The results of this study
are in agreement with the findings of these previous investiga-
tions. The subgroup of patients in the Hirulog Angioplasty
Table 2. Ischemic Complications According to Presence of Thrombus-Containing Lesions
on Angiography
Complication
Thrombus
(n 5 567)
No Thrombus
(n 5 3,488) OR (95% CI) p Value
Death 4 (0.7) 8 (0.2) 3.2 (1.0–10.3) 0.07
MI 29 (5.1) 112 (3.2) 1.6 (1.1–2.5) 0.03
Emergency bypass surgery 11 (1.9) 54 (1.5) 1.3 (0.7–2.4) 0.47
Death, MI or bypass surgery 39 (6.9) 153 (4.4) 1.6 (1.1–2.3) 0.01
Abrupt vessel closure 77 (13.6) 291 (8.3) 1.7 (1.3–2.3) , 0.001
Data presented are number (%) of patients. CI 5 confidence interval; MI 5 myocardial infarction; OR 5 odds ratio.
Table 1. Baseline Clinical Characteristics of Patients Undergoing
Coronary Angioplasty With Thrombus-Containing Lesions
According to Treatment Group
Characteristic
Bivalirudin
(n 5 301)
Heparin
(n 5 266) p Value
Median age (yr) 61 62 0.83
(25th, 75th percentiles) (56, 66) (56, 67)
Female gender 76 (25) 75 (28) 0.45
Diabetes 52 (17) 50 (19) 0.66
Cigarette use 81 (27) 69 (26) 0.85
Unstable angina 213 (71) 187 (70) 0.93
Pain at rest within
48 h before angioplasty 193 (64) 192 (72) 0.05
Postinfarction angina 88 (29) 79 (30) 0.93
Multivessel coronary disease 139 (46) 136 (51) 0.27
Heparin pretreatment 100 (34) 119 (46) 0.004
ACT at 5 min (s) 348 382 , 0.001
(25th, 75th percentiles) (318, 390) (342, 427)
Lesion type*
Total occlusion 148 (49) 141 (53) 0.40
Filling defect 50 (17) 45 (17) 1.0
Hazy ulcerated lesion 112 (37) 86 (32) 0.25
*Some patients had more than one lesion type. Data presented are number
(%) of patients, unless otherwise indicated. ACT 5 activated clotting time.
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Study with thrombus-containing lesions on angiography expe-
rienced a higher incidence of myocardial infarction and abrupt
closure of the dilated vessel compared with the remainder of
the cohort who did not have angiographic evidence of throm-
bus.
Thrombin bound to fibrin is enzymatically active and has
the ability to stimulate further thrombin generation, platelet
aggregation and fibrin polymerization (1), which accounts for
the difficulty in treating intracoronary thrombus. At the
present time, aspirin and heparin continue to be the standard
antithrombotic therapies for patients who have unstable an-
gina pectoris (34). The direct thrombin inhibitors, however,
have several theoretic advantages as antithrombotic agents
over heparin. Unlike heparin, the direct thrombin inhibitors do
not require a cofactor to exert their effects; they are active
against clot-bound thrombin (1); and they have no natural
inhibitors (2). In addition, the direct thrombin inhibitors have
stable pharmacodynamic and pharmocokinetic properties and
have been shown to provide stable levels of anticoagulation
(5,35). Given their potential advantages, we hypothesized that
patients with angiographically demonstrable thrombus as the
cause of their unstable coronary syndrome would experience
fewer ischemic complications after angioplasty when treated
with the direct thrombin inhibitor, bivalirudin, compared with
heparin. The results of our study, however, suggest that
treatment with bivalirudin is not more effective than treatment
with heparin in this high risk subgroup of patients. The
incidence of in-hospital death, myocardial infarction, need for
emergency bypass surgery and abrupt vessel closure was the
same in both treatment groups. The treatments were also
equivalent in preventing ischemic complications over a 6-
month period after angioplasty.
Explanations for observations. There are several potential
explanations for the apparent equivalence of bivalirudin and
heparin for thrombus-containing lesions. First, both the direct
thrombin inhibitors and heparin have a small, if any, effect on
platelet aggregation and activation. Several investigators have
suggested that thrombus in unstable angina is platelet rich in
contrast to thrombus in acute myocardial infarction, which has
a large fibrin component (18,36,37). Fuster et al. (18) have
postulated that whether rupture of an atheromatous plaque
results in unstable angina or acute myocardial infarction
depends on the severity of the associated vascular injury. With
mild vascular injury, platelets immediately bind to the suben-
dothelium through the interaction of platelet glycoproteins
with von Willebrand factor and collagen on the vessel wall. It
is not until platelets have been activated or there has been
severe vascular injury with exposure of tissue factor and types
I and III collagen that the coagulation cascade is activated and
there is activation of thrombin associated with fibrin deposition
(18). Davies et al. (36) have suggested that thrombus formation
that occurs after plaque rupture occurs in three stages. In the
first stage, there is intraintimal hemorrhage and thrombus
formation that is platelet rich. In the second stage, intramural
but not occlusive thrombus is formed, which tends to have
more of a fibrin component due to the thrombogenicity of the
activated platelets in the first stage. Pathologic studies by Falk
(12) suggest that recurrent episodes of plaque rupture and
intramural thrombus formation may be the cause of unstable
angina in patients with coronary disease. It is not until the third
stage that there is intense thrombin activation and occlusive
thrombus formation that leads to transmural infarction. An-
gioscopic studies have confirmed the differences between the
thrombus which forms in unstable angina and that which forms
in acute myocardial infarction (11). Thrombus in unstable
angina often has a gray-white appearance, whereas that in
transmural infarction is red in appearance, suggesting that
thrombin generation and fibrin deposition are not as intense in
unstable angina. Therefore, given that bivalirudin does not
directly inhibit platelet aggregation and that thrombin activa-
tion with fibrin deposition appears to play a smaller role than
platelet aggregation in unstable angina, bivalirudin may not be
expected to offer an advantage over heparin in the treatment of
thrombus-containing lesions.
Another potential explanation for the results of this study is
that the direct thrombin inhibitors may not be more effective
than heparin at inhibiting the generation of thrombin. Heparin
requires the cofactor antithrombin III to inactivate thrombin,
whereas bivalirudin binds directly to thrombin. Antithrombin
III, however, also inactivates coagulation factors Xa, XIIa, XIa
and IXa (38), perhaps providing an advantage over the direct
thrombin inhibitors in preventing thrombin generation. Bio-
chemical studies have shown that for equivalent levels of
prothrombin fragment F1.2 generation (reflecting thrombin
Table 3. Ischemic Complications in Patients With Thrombus-Containing Lesions on Angiography
According to Treatment Group
Complication
Bivalirudin
(n 5 301)
Heparin
(n 5 266) OR (95% CI) p Value
Death 3 (1.0) 1 (0.4) 2.1 (0.3–14.2) 0.63
MI 16 (5.3) 13 (4.9) 1.1 (0.5–2.3) 0.85
Emergency bypass surgery 6 (2.0) 5 (1.9) 1.1 (0.3–3.5) 1.0
Death, MI or bypass surgery 21 (7.0) 18 (6.8) 1.0 (0.5–2.0) 1.0
Abrupt vessel closure 44 (14.6) 33 (12.4) 1.2 (0.7–2.0) 0.46
Death, MI or repeat
revascularization at 6 mo
81 (26.9) 72 (27.1) 1.0 (0.7–1.4) 0.95
Data presented are number (%) of patients. Abbreviations as in Table 2.
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generation), fibrinopeptide A generation (reflecting thrombin
activity) is lower with the direct thrombin inhibitor, hirudin,
than with heparin; however, for equivalent levels of fibrino-
peptide A generation, there is a greater reduction of F1.2
generation with heparin than with hirudin (39,40). Therefore,
despite better direct thrombin inhibition, the direct thrombin
inhibitors do not appear to be as effective as heparin in
preventing thrombin generation, which may limit their efficacy
as antithrombotic agents compared with heparin. Further-
more, thrombin is the most potent stimulant of platelet
aggregation, and the inability of the direct thrombin inhibitors
to reduce thrombin generation is associated with inefficient
inhibition of platelet aggregation as well (41).
A third explanation for why this study showed no difference
between bivalirudin and heparin is that the study was not
powered to detect a clinically meaningful difference between
the treatment groups. With ;300 patients in both treatments
groups, this study could detect an 11% or greater reduction in
the combined primary end point in the bivalirudin treatment
group compared with the heparin treatment group at 90%
power. Therefore, this study does not exclude the possibility
that a smaller, statistically significant difference may exist
between the two treatment groups.
Postinfarction angina. In the Hirulog Angioplasty Study,
patients with postinfarction angina who were treated with
bivalirudin experienced fewer in-hospital ischemic complica-
tions after angioplasty compared with their counterparts who
were treated with heparin. Postinfarction angina is a syndrome
that is highly associated with recurrent intracoronary thrombus
formation (8,15,19). In this study, however, this benefit of
bivalirudin was not seen in all patient subgroups with clear
angiographic evidence of thrombus. One explanation for this
observation is that it is possible that not all patients with
angiographic evidence of thrombus in fact had active intra-
coronary thrombus. For instance, some of the total occlusions
may have represented progressive atherosclerotic disease or
old organized thrombus that would not be expected to benefit
from treatment with a direct thrombin inhibitor. Another
explanation is that this subgroup analysis eliminated the effect
of randomization and introduced inequalities in the treatment
groups, which could have affected the outcome of the study.
For instance, patients in the heparin treatment group were
more likely to have received pretreatment with heparin before
randomization than patients in the bivalirudin treatment
group. Prolonged heparin in patients with unstable angina
associated with intracoronary thrombus reduces ischemic com-
plications after angioplasty (42), and this may have improved
the outcomes of the heparin treatment group in this study.
Other approaches for thrombus-containing lesions. Sev-
eral potential approaches may be used to improve the efficacy
of bivalirudin for patients undergoing coronary angioplasty for
thrombus-containing lesions. The activated clotting time dur-
ing angioplasty was significantly lower for patients in the
bivalirudin treatment group, suggesting that a higher dose of
bivalirudin may be more effective. The dose of bivalirudin used
in this study was carefully chosen based on a previous phase II
trial that evaluated the safety of bivalirudin (4). In fact, the
dose of bivalirudin used in this study was the highest dose of
bivalirudin used in any clinical trial to date. A higher dose of
bivalirudin, however, may be accompanied by a higher inci-
dence of bleeding complications. Another carefully performed
study would be needed to confirm that a higher dose of
bivalirudin will sufficiently reduce ischemic complications after
angioplasty, albeit with a potentially higher risk of bleeding
complications.
Other antithrombotic approaches may be helpful in the
treatment of thrombus-containing lesions. The direct thrombin
inhibitors have been shown to be equivalent or only slightly
more efficacious than heparin in several large-scale trials
evaluating their use in a variety of acute coronary syndromes
(43–45). In contrast, inhibition of the platelet glycoprotein
IIb/IIIa receptor has been shown to significantly reduce both
in-hospital and long-term ischemic complications in high risk
patients undergoing coronary angioplasty for unstable angina
(46,47). Also, as previously discussed, thrombus in unstable
angina may have a larger platelet component than fibrin
component, suggesting that IIb/IIIa receptor inhibition may be
more effective in the treatment of these lesions.
Conclusions. Overall, bivalirudin appears to be a safe and
effective alternative to heparin for use in a variety of coronary
syndromes. This investigational direct thrombin inhibitor may
prove to be a useful alternative in situations where heparin is
not tolerated, such as in patients who develop heparin-induced
thrombocytopenia.
The results of this study suggest that bivalirudin is equiva-
lent to heparin in reducing ischemic complications after angio-
plasty for thrombus-containing lesions. Patients undergoing
coronary angioplasty for thrombus-containing lesions continue
to be at high risk for ischemic complications after angioplasty.
Other antithrombotic therapies, specifically aimed at reducing
platelet activation and aggregation, may be more efficacious in
reducing ischemic complications in this high risk subgroup of
patients.
References
1. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound
thrombin is protected from inhibition by heparin–antithrombin III but is
susceptible to inactivation by antithrombin III–independent inhibitors. J Clin
Invest 1990;86:385–91.
2. Eitzman DT, Chi L, Saggin L, Schwartz RS, Lucchesi BR, Fay WP. Heparin
neutralization by platelet-rich thrombi: role of platelet factor 4. Circulation
1994;89:1523–9.
3. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin:
mechanism of action, pharmacokinetics, dosing considerations, monitoring,
efficacy, and safety. Chest 1995;108:258S–75S.
4. Topol EJ, Bonan R, Jewitt D, et al. Use of a direct antithrombin, hirulog, in
place of heparin during coronary angioplasty. Circulation 1993;87:1622–9.
5. Fuchs J, Cannon CP, and the TIMI 7 Investigators. Hirulog in the treatment
of unstable angina: results of the Thrombin Inhibition in Myocardial
Ischemia (TIMI) 7 trial. Circulation 1995;92:727–33.
6. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (hirulog) as
compared with heparin during coronary angioplasty for unstable or postin-
farction angina. N Engl J Med 1995;333:764–9.
7. Ambrose JA, Winters SL, Stern A, et al. Angiographic morphology and the
pathogenesis of unstable angina pectoris. J Am Coll Cardiol 1985;5:609–16.
1268 SHAH ET AL. JACC Vol. 30, No. 5
BIVALIRUDIN VS. HEPARIN DURING CORONARY ANGIOPLASTY November 1, 1997:1264–9
8. Ahmed WH, Bittl JA, Braunwald E. Relation between clinical presentation
and angiographic findings in unstable angina pectoris, and comparison with
that in stable angina. Am J Cardiol 1993;72:544–50.
9. Gotoh K, Minamino T, Katoh O, et al. The role of intracoronary thrombus
in unstable angina: angiographic assessment and thrombolytic therapy
during ongoing anginal attacks. Circulation 1988;77:526–34.
10. Sherman CT, Litvack F, Grundfest W, et al. Coronary angioscopy in patients
with unstable angina pectoris. N Engl J Med 1986;315:913–9.
11. Mizuno K, Satomura K, Miyamoto A, et al. Angioscopic evaluation of
coronary-artery thrombi in acute coronary syndromes. N Engl J Med
1992;326:287–91.
12. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis
leading to infarction and/or sudden death. Circulation 1985;71:699–708.
13. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial
infarction, sudden ischaemic death, and crescendo angina. Br Heart J
1985;53:363–73.
14. Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial
platelet aggregation in patients with unstable angina suffering ischemic
cardiac death. Circulation 1986;73:418–27.
15. Bentivoglio LG, Detre K, Yeh W, Williams DO, Kelsey SF, Faxon DP.
Outcome of percutaneous transluminal coronary angioplasty in subsets of
unstable angina pectoris. J Am Coll Cardiol 1994;24:1195–206.
16. Rehr R, Disciascio G, Vetrovec G, Cowley M. Angiographic morphology of
coronary artery stenoses in prolonged rest angina: evidence of intracoronary
thrombosis. J Am Coll Cardiol 1989;14:1429–37.
17. Teirstein PS, Schatz RA, Denardo SJ, Jensen EE, Johnson AD. Angioscopic
versus angiographic detection of thrombus during coronary interventional
procedures. Am J Cardiol 1995;75:1083–7.
18. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro
J. Insights into the pathogenesis of acute ischemic syndromes. Circulation
1988;77:1213–20.
19. Tabata H, Mizuno K, Arakawa K, et al. Angioscopic identification of
coronary thrombus in patients with postinfarction angina. J Am Coll Cardiol
1995;25:1282–5.
20. Wolfe MW, Roubin GS, Schweiger M, et al. Length of hospital stay and
complications after percutaneous transluminal coronary angioplasty: clinical
and procedural predictors. Circulation 1995;92:311–9.
21. The prognostic importance of the electrocardiogram after myocardial infarc-
tion: experience in the Coronary Drug Project. Ann Intern Med 1972;77:
677–89.
22. Detre KM, Holmes DR Jr, Holubkov R, et al. Incidence and consequences
of periprocedural occlusion: the 1985–1986 National Heart, Lung, and Blood
Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circu-
lation 1990;82:739–50.
23. The TIMI Research Group. Immediate versus delayed catheterization and
angioplasty following thrombolytic therapy for acute myocardial infarction:
TIMI II A results. JAMA 1988;260:2849–58.
24. Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting for acute
and threatened closure complicating percutaneous transluminal coronary
angioplasty. Circulation 1992;85:916–27.
25. Uehata A, Matsugushi T, Bittl JA, et al. Accuracy of electronic digital
calipers compared with quantitative angiography in measuring arterial
diameter. Circulation 1993;88:1724–9.
26. Vetrovec GW, Leinbach RC, Gold HK, Cowley MJ. Intracoronary throm-
bolysis in syndromes of unstable ischemia: angiographic and clinical results.
Am Heart J 1982;104:946–52.
27. Rosner B. Regression and correlation methods. In: Rosner B, editor.
Fundamentals of Biostatistics. 3rd ed. Boston: PWS-Kent, 1990:455–8.
28. Zar JH. Biostatistical Analysis. 2nd ed. Englewood Cliffs (NJ): Prentice-Hall,
1984:122–49.
29. Freeman MR, Williams AE, Chisholm RJ, Armstrong PW. Intracoronary
thrombus and complex morphology in unstable angina: relation to timing of
angiography and in-hospital cardiac events. Circulation 1989;80:17–23.
30. Ellis SG, Roubin GS, King SB III, et al. Angiographic and clinical predictors
of acute closure after native vessel coronary angioplasty. Circulation 1988;
77:372–9.
31. White CJ, Ramee SR, Collins TJ, et al. Coronary thrombi increase PTCA
risk: angioscopy as a clinical tool. Circulation 1996;93:253–8.
32. Mabin TA, Holmes DR, Smith HC, et al. Intracoronary thrombus: role in
coronary occlusion complicating percutaneous transluminal coronary angio-
plasty. J Am Coll Cardiol 1985;5:198–202.
33. Myler RK, Shaw RE, Stertzer SH, et al. Lesion morphology and coronary
angioplasty: current experience and analysis. J Am Coll Cardiol 1992;19:
1641–52.
34. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat
acute unstable angina. N Engl J Med 1988;319:1105–11.
35. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant
desulfatohirudin compared with heparin in conjunction with tissue-type
plasminogen activator and aspirin for acute myocardial infarction: results of
the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol
1994;23:993–1003.
36. Davies MJ. Thrombosis and coronary atherosclerosis. In: Julian D, Kubler
W, Norris RM, Swan HJC, Collen D, Verstraete M, editors. Thrombolysis in
Cardiovascular Disease. New York: Marcel Dekker, 1989:25–43.
37. Ambrose JA. Plaque disruption and the acute coronary syndromes of
unstable angina and myocardial infarction: if the substrate is similar, why is
the clinical presentation different? J Am Coll Cardiol 1992;19:1653–8.
38. Rosenberg RD, Bauer KA. The heparin-antithrombin system: a natural
anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, Salzman
EW, editors. Hemostasis and Thrombosis: Basic Principles and Clinical
Practice. 3rd ed. Philadelphia: J.B. Lippincott, 1994:837–60.
39. Zoldheyi P, Janssens S, Lefe`vere G, Collen D, Van de Werf F, for the
GUSTO-2a Investigators. Effects of heparin and hirudin (CGP 39393) on
thrombin generation during thrombolysis for acute myocardial infarction
[abstract]. Circulation 1995;92 Suppl I:I-740.
40. Rao AK, Sun L, Chesebro JH, et al. Distinct effects of recombinant
desulfatohirudin CGP 39,393 and heparin on plasma levels of fibrinopeptide
A and prothrombin fragment F1.2 in unstable angina: a multicenter trial
[abstract]. Thromb Haemost 1995;73:1306.
41. Gallistl S, Muntean W, Leis HJ. Effects of heparin and hirudin on thrombin
generation and platelet aggregation after intrinsic activation of platelet rich
plasma. Thromb Haemost 1995;74:1163–8.
42. Laskey MAL, Deutsch E, Barnathan E, Laskey WK. Influence of heparin
therapy on percutaneous coronary transluminal angioplasty outcome in
patients with coronary arterial thrombosis. Am J Cardiol 1990;65:179–82.
43. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial
infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction
(TIMI) 9B trial. Circulation 1996;94:911–21.
44. The Global Use of Strategies to Open Occluded Coronary Arteries (GUS-
TO) IIb Investigators. A comparison of recombinant hirudin with heparin
for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775–
82.
45. Serruys PW, Herrman JR, Simon R, et al. A comparison of hirudin with
heparin in the prevention of restenosis after coronary angioplasty. N Engl
J Med 1995;333:757–63.
46. The EPIC Investigators. Use of a monoclonal antibody directed against the
platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
N Engl J Med 1994;330:956–61.
47. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary
intervention with antibody against platelet IIb/IIIa integrin for reduction of
clinical restenosis: results at six months. Lancet 1994;343:881–6.
1269JACC Vol. 30, No. 5 SHAH ET AL.
November 1, 1997:1264–9 BIVALIRUDIN VS. HEPARIN DURING CORONARY ANGIOPLASTY
